BioStock: Arcede aims for clinic with TO1

Preparations for clinical trials continue for the Lund-based drug developer Arcede Pharma. Right now, the focus is on finding the right dose and concentration of RCD405 to use in the upcoming phase I studies. January 8 to 19 is the exercise period for the TO1 warrant, which is intended to finance the preparations.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/01/arcede-aims-for-clinic-with-to1/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se